Article

Vasodilator Activity of Compounds Isolated from Plants Used in Mexican Traditional Medicine

Francisco J. Luna-Vázquez [1] , **César Ibarra-Alvarado** [1,*]**, María del Rayo Camacho-Corona** [2,*]**,**
Alejandra Rojas-Molina [1]**, J. Isela Rojas-Molina** [1]**, Abraham García** [2] **and Moustapha Bah** [1]

[1] Laboratorio de Investigación Química y Farmacológica de Productos Naturales, Facultad de Química,
Universidad Autónoma de Querétaro, C.P. 76010 Querétaro, Mexico; fjlunavz@yahoo.com.mx (F.J.L.-V.);
rojasa@uaq.mx (A.R.-M.); jirojas@gmail.com (J.I.R.-M.); moubah@uaq.mx (M.B.)

[2] Universidad Autónoma de Nuevo León, Facultad de Ciencias Químicas, Ciudad Universitaria,
San Nicolás de los Garza, CP 66451 Nuevo León, Mexico; edgar.garciazp@uanl.edu.mx

* Correspondence: cibarra@uaq.com (C.I.-A.); maria.camachocn@uanl.edu.mx (M.d.R.C.-C.);
Tel.: +52-442-1921200 (ext. 5527) (C.I.-A.); +52-81-8329-4000 (ext. 3414) (M.d.R.C.-C.)

check for
updates

Abstract: Arterial hypertension is one of the main risk factors in the development of cardiovascular diseases. Therefore, it is important to look for new drugs to treat hypertension. In this study, we carried out the screening of 19 compounds (triterpenes, diterpenes, sesquiterpenes, lignans, and flavonoids) isolated from 10 plants used in Mexican traditional medicine to determine whether they elicited vascular smooth muscle relaxation and, therefore, could represent novel anti-hypertension drug candidates. The vasorelaxant activity of these compounds was evaluated on the isolated rat aorta assay and the results obtained from this evaluation showed that three compounds induced a significant vasodilatory effect: *meso*-dihydroguaiaretic acid [half maximal effective concentration (EC$_{50}$), 49.9 $\pm$ 11.2 μM; maximum effect (Emax), 99.8 $\pm$ 2.7%]; corosolic acid (EC$_{50}$, 108.9 $\pm$ 6.7 μM; Emax, 96.4 $\pm$ 4.2%); and 5,8,4′-trihydroxy-3,7-dimethoxyflavone (EC$_{50}$, 122.3 $\pm$ 7.6 μM; Emax, 99.5 $\pm$ 5.4%). Subsequently, involvement of the NO/cyclic guanosine monophosphate (cGMP) and H$_2$S/ATP-sensitive potassium channel (K$_{ATP}$) pathways on the vasodilator activity of these compounds was assessed. The results derived from this analysis showed that the activation of both pathways contributes to the vasorelaxant effect of corosolic acid. On the other hand, the vasodilator effect of *meso*-dihydroguaiaretic acid and 5,8,4′-trihydroxy-3,7-dimethoxyflavone, partly involves stimulation of the NO/cGMP pathway. However, these compounds also showed an important endothelium-independent vasorelaxant effect, whose mechanism of action remains to be clarified. This study indicates that *meso*-dihydroguaiaretic acid, corosolic acid, and 5,8,4′-trihydroxy-3,7-dimethoxyflavone could be used as lead compounds for the synthesis of new derivatives with a higher potency to be developed as drugs for the prevention and treatment of cardiovascular diseases.

Keywords: corosolic acid; 5,8,4′-trihydroxy-3,7-dimethoxyflavone; *meso*-dihydroguaiaretic acid hydrogen sulfide; nitric oxide; vasorelaxation

1. Introduction

Arterial hypertension is considered a major risk factor in the development of several cardiovascular diseases, such as myocardial infarction and stroke [1–3], which together were responsible for 15 million deaths in 2015 [4]. Although several drugs are currently used in the treatment of high blood pressure, less than a third of the hypertension cases are successfully treated [5–8].

It has been broadly demonstrated that endothelial dysfunction, characterized by a diminished availability of endothelial relaxing factors, significantly contributes to the development of hypertension

and thus, other cardiovascular diseases [9–11]. Particularly, reduced release of the gasotransmitters NO and H_2S results in an impaired regulation of the vascular tone [12–14]. Therefore, the NO/cyclic guanosine monophosphate (cGMP) and H_2S/ATP-sensitive potassium channel (K_{ATP}) pathways are valuable targets for innovative treatments in hypertension [12–14].

In Mexico, plants are an important element of traditional medicine, and many of them are considered part of Mexican cultural heritage from prehispanic and colonial times [15,16]. Nevertheless, relatively few systematic scientific studies have been conducted to fully characterize the chemical composition and pharmacological activities of Mexican medicinal plants.

In the present study, we carried out a pharmacological screening of 19 secondary metabolites isolated from 10 plants used in Mexican traditional medicine in order to detect leads that could be developed as potential drug candidates to treat hypertension. The plant sources of the tested compounds were: *Amphipterygium adstringens* (Schltdl.) Standl. (*cuachalalate*), *Celaenodendron mexicanum* Standl. (*palo prieto*), *Crataegus gracilior* J.B. Phipps (*tejocote*), *Croton alamosanus* Rose (*vara blanca*), *Croton glabellus* L. (*cascarillo*), *Galphimia glauca* Cav. (*árnica roja*), *Jatropha neopauciflora Pax* (*sangre de grado*), *Larrea tridentata* (Sessé and Moc. ex DC.) Coville (*gobernadora*), *Perezia adnata* A. Gray (*pipitzáhuac*), and *Teloxys graveolens* (*epazote de zorrillo*). These plants are widely used in Mexican traditional medicine to treat several illnesses, such as gastric ulcers, stomach ache, gastroenteritis, diarrhea, dysentery, sores and infections of the oral cavity, skin ulcers [17–21], renal disorders and kidney stones (*Larrea tridentata*) [17], cough, asthma, tachycardia and to improve coronary blood flow (*Crataegus gracilior*) [20,22], and cancer (*Croton alamosanus*) [23].

The compounds evaluated were previously purified by our research group and our collaborators [18,19,24–26] and include: (a) triterpenes: 3-α-hydroxymasticadienonic acid (**1**), 3α-hydroxytirucalla-7,22Z-dien-26-oic acid (**2**), corosolic acid (**3**), galphin A (**4**), galphin B (**5**), galphimidin (**6**), and 3β-*trans-p*-coumaroyl-oxy-16-β-hydroxy-20(29)-lupene (**7**); (b) sterols: β-sitosteryl β-D-glucopyranoside (**8**); (c) diterpenes: (3*R*,4*R*,6*S*)-*p*-menth-1-eno-3,6-diol (**9**), 6,7-diacetylaustro inulin (**10**), and 6-*O*-acetylaustro inulin (**11**); (d) sesquiterpenes: perezone (**12**), and pipitzol (**13**); (e) lignans: 3′-demethoxy-6-*O*-demethyl-isoguaiacin (**14**) and *meso*-dihydroguaiaretic acid (**15**); and (f) flavonoids: 5,4′-dihydroxy-3,7,8-trimethoxyflavone (**16**), 5-hydroxy-3,7,4′-trimethoxyflavone (**17**), 5,8,4′-trihydroxy-3,7-dimethoxyflavone (**18**), and pinostrobin (**19**) (Figure 1). Although it has been previously demonstrated that some of these compounds possess biological activities, such as antibacterial and antifungal [21,25,27], antiprotozoal [18,24,28,29], anti-inflammatory [30], anti-diabetic [31,32], and anticancer [23], at present, there are no studies aimed at assessing their vasodilatory activity.

In the first phase of this study, we assessed whether the selected compounds elicited vascular smooth muscle relaxation in the isolated rat aorta. Thereafter, the most potent vasodilator compounds, which also displayed the highest maximum effects [maximum effect (Emax) ≥ 96%], were evaluated to determine if the NO/cGMP and H_2S/K_{ATP} channel pathways were involved in their mechanism of action.


**Figure 1.** *Cont.*

Figure 1. *Cont.*

Figure 1. Chemical structures of studied compounds.

2. Results

The results from the pharmacological evaluation of the selected compounds indicated that 3-α-hydroxymasticadienonic acid (**1**), corosolic acid (**3**), galphimidin (**6**), *meso*-dihydroguaiaretic acid (**15**), 5,8,4′-trihydroxy-3,7-dimethoxyflavone (**18**), and pinostrobin (**19**) elicited a significant vasodilation. All these six secondary metabolites exhibited a maximum vasodilator effect up to 96%, which was higher than that of Acetylcholine (ACh), used as the positive control (Table 1). *meso*-Dihydroguaiaretic acid (**15**) exhibited a comparable potency to that of Ach, while corosolic acid (**3**) and 5,8,4′-trihydroxy-3,7-dimethoxyflavone (**18**) turned out to be approximately two-fold less potent than the positive control (Figure 2 and Table 1). Based on these results, involvement of the NO/cGMP and H_2S/K_{ATP} channel pathways in the mechanisms underlying the vasorelaxant action of *meso*-dihydroguaiaretic acid (**15**) and 5,8,4′-trihydroxy-3,7-dimethoxyflavone (**18**), both isolated from *Larrea tridentata*, and corosolic acid (**3**) purified from *Crataegus gracilior*, was analyzed.

Table 1. Values of half maximal effective concentration (EC_{50}) and maximum effect (Emax) of positive control (Acetilcholine, ACh) and test compounds.

Plant/Compound	EC_{50} (µM)	E_{max} (%)
acetilcholine (ACh)	58.8 ± 8.9	69.5 ± 5.7
Amphypterygium adstringens		
3-α-hydroxymasticadienonic acid (**1**)	206.1 ± 11.6	98.2 ± 3.1
Celaenodendron mexicanum		
3α-hydroxytirucalla-7,22Z-dien-26-oic acid (**2**)	331.3 ± 42.1	99.5 ± 6.1
Crataegus gracilior		
Corosolic acid (**3**)	108.9 ± 6.7	96.4 ± 4.2
Croton alamosanus		
5-hydroxy-3,7,4′-trimethoxyflavone (**17**)	377.1 ± 37.1	80.5 ± 3.7
(3*R*,4*R*,6*S*)-*p*-menth-1-ene-3,6-diol (**9**)	1622.8 ± 73.8	99.5 ± 8.3
Croton glabellus		
6-*O*-acetylaustro inulin (**10**)	413.5 ± 22.4	47.1 ± 2.8
6,7-diacetylaustro inulin (**11**)	261.0 ± 9.1	99.5 ± 3.8
Galphimia glauca		
Galphin A (**4**)	592.3 ± 21.7	99.5 ± 9.1
Galphin B (**5**)	1030.7 ± 39.4	99.5 ± 23.2
Galphimidin (**6**)	145.9 ± 9.2	99.5 ± 5.3
Jatropha neopauciflora		
3β-*trans*-*p*-coumaroyl-oxy-16-β-hydroxy-20(29)-lupene (**7**)	63.2 ± 5.8	27.5 ± 1.9
β-sitosteryl β-D-glucopyranoside (**8**)	314.7 ± 19.7	71.2 ± 5.3
Larrea tridentata		
meso-dihydroguaiaretic acid (**15**)	49.9 ± 11.2	99.8 ± 2.7
5,4′-dihydroxy-3,7,8-trimethoxyflavone (**16**)	587.8 ± 33.4	80.5 ± 5.6
5,8,4′-trihydroxy-3,7-dimethoxyflavone (**18**)	122.3 ± 7.6	99.5 ± 5.4
3′-demethoxy-6-*O*-demethyl-isoguaiacin (**14**)	604.5 ± 60.1	91.70 ± 7.3
Perezia adnata		
perezone (**12**)	524.5 ± 32.5	99.5 ± 2.2
pipitzol (**13**)	249.4 ± 10.2	59.8 ± 2.4
Teloxys graveolens		
pinostrobin (**19**)	234.9 ± 9.9	99.5 ± 4.8

Figure 2. Concentration-response curves of the vasodilator effect of corosolic acid (**3**), *meso*-dihydroguaiaretic acid (**15**), and 5,8,4′-trihydroxy-3,7-dimethoxyflavone (**18**). Acetylcholine was used as a positive control.

2.1. Participation of the Endothelium in the Vasorelaxant Response of Compounds **3**, **15**, and **18**

Figure 3 shows the concentration-response curves (CRCs) for corosolic acid (**3**), *meso*-dihydroguaiaretic acid (**15**), and 5,8,4′-trihydroxy-3,7-dimethoxyflavone (**18**) in the presence and absence of endothelium.


Figure 3. Concentration-response curves of the vasodilator effect of (**a**) corosolic acid (**3**), (**b**) *meso*-dihydroguaiaretic acid (**15**), and (**c**) 5,8,4′-trihydroxy-3,7-dimethoxyflavone (**18**) in the presence and absence (E-) of endothelium. A typical trace in which *meso*-dihydroguaiaretic acid (**15**) inhibited Phe-induced contraction in endothelium-intact (**d**), and -denuded aorta (**e**). Analysis by an unpaired *t*-test was made to test for differences between EC$_{50}$s of each compound in the presence and absence of endothelium (**3**, $p < 0.0001$; **15**, $p < 0.0001$; **18**, $p = 0.0093$).

The vasorelaxation induced by corosolic acid (**3**) was almost completely blocked in the absence of endothelium, which suggested that endothelial factors mediate its vasodilatory effect. On the other hand, endothelial denudation caused a significant rightward shift of the CRC to *meso*-dihydroguaiaretic acid (**15**) and 5,8,4′-trihydroxy-3,7-dimethoxyflavone (**18**), indicating the contribution of both endothelium-independent and dependent pathways in their mechanism of action.

2.2. Participation of the NO/cGMP and H$_2$S/K$_{ATP}$ Channel Pathways in the Vasodilator Response of Compounds **3**, **15**, and **18**

The effect of N^G-nitro-l-arginine methyl ester (L-NAME, 100 μM), an inhibitor of endothelial nitric oxide synthase, on the vasorelaxation induced by compound **3** closely resembled that which occurred in the absence of endothelium, clearly supporting that activation of the NO/cGMP pathway importantly contributes to corosolic acid (**3**)-vasodilation. Regarding *meso*-dihydroguaiaretic acid (**15**)-induced vasodilation, it was significantly reduced ($p = 0.006$), but not completely blocked, in the

presence of L-NAME, indicating that the effect of this lignan partly depends on stimulation of the NO/cGMP pathway. On the other hand, the inhibition of endothelial nitric oxide synthase (eNOS) with L-NAME produced a slight rightward shift of the CRC of 5,8,4′-trihydroxy-3,7-dimethoxyflavone (**18**) (*p* = 0.99) (Figure 4).


Figure 4. Vasodilatory effect of (**a**) corosolic acid (**3**), (**b**) *meso*-dihydroguaiaretic acid (**15**), and (**c**) 5,8,4′-trihydroxy-3,7-dimethoxyflavone (**18**) in the absence (control) and presence of L-NAME (100 μM). Analysis by one-way analysis of variance (ANOVA) was made between the curves of each compound in the absence and presence of N^G-nitro-l-arginine methyl ester (L-NAME) followed by a post hoc Tukey's test (**3**, *p* < 0.0001; **15**, *p* = 0.006; **18**, *p* = 0.991).

To determine whether the H_2S/K_{ATP} pathway participated in the vasodilatory effect of compounds **3**, **15**, and **18**, the effect of propargylglycine (PAG; 1 mM), an inhibitor of cystathionine gamma-lyase (CSE), was assessed. This inhibitor significantly decreased the maximum vasodilator effect of corosolic acid (**3**) from ~97% to ~50%, which supported the idea that the H_2S/K_{ATP} channel pathway is also involved in the vasorelaxant mechanism of this compound. By contrast, the presence of PAG did not significantly modify the CRCs of *meso*-dihydroguaiaretic acid (**15**) and 5,8,4′-trihydroxy-3,7-dimethoxyflavone (**18**), discarding involvement of the H_2S/K_{ATP} pathway in their effect (Figure 5).


Figure 5. Vasodilatory effect of (**a**) corosolic acid (**3**), (**b**) *meso*-dihydroguaiaretic acid (**15**), and (**c**) 5,8,4′-trihydroxy-3,7-dimethoxyflavone (**18**) in the absence (control) and presence of propargylglycine (PAG, 1 mM). Analysis by one-way ANOVA was made between the curves of each compound in the absence and presence of PAG followed by a post hoc Tukey's test (**3**, *p* = 0.001; **15**, *p* = 0.803; **18**, *p* = 0.102).

2.3. Involvement of K⁺ Channels in the Vasodilation Evoked by Compounds 3, 15, and 18

2.3. Involvement of K⁺ Channels in the Vasodilation Evoked by Compounds **3**, **15**, *and* **18**

To test whether the activation of K^+ channels was implicated in the vasodilatory effect of compounds **3**, **15**, and **18**, tetraethylammonium (TEA) was used to block K^+ channels. TEA pre-treatment significantly reduced the corosolic acid (**3**)-vasorelaxant effect, without significantly altering the CRCs of *meso*-dihydroguaiaretic acid (**15**) and 5,8,4′-trihydroxy-3,7-dimethoxyflavone (**18**) (Figure 6).


Figure 6. Vasodilatory effect of (**a**) corosolic acid (**3**), (**b**) *meso*-dihydroguaiaretic acid (**15**), and (**c**) 5,8,4′-trihydroxy-3,7-dimethoxyflavone (**18**) in the absence (control) and presence of tetraethylammonium (TEA, 10 mM). Analysis by one-way ANOVA was made between the curves of each compound in the absence and presence of TEA followed by a post hoc Tukey's test (**3**, $p < 0.0001$; **15**, $p = 0.868$; **18**, $p = 0.429$).

3. Discussion

In the present study, we carried out the pharmacological evaluation of 19 natural products, which we had previously isolated from 10 plants widely used in Mexican traditional medicine, in the search of leads that could be used to develop new therapeutic agents to treat cardiovascular diseases.

All compounds tested caused a concentration-related relaxation of L-phenylephrine-contracted rat aortic rings. It is important to highlight that 3-α-hydroxymasticadienonic acid (**1**), corosolic acid (**3**), galphimidin (**6**), *meso*-dihydroguaiaretic acid (**15**), 5,8,4′-trihydroxy-3,7-dimethoxyflavone (**18**), and pinostrobin (**19**) exhibited a maximum vasodilator effect higher than that of acetylcholine. Of these six compounds, the most potent were corosolic acid (**3**), *meso*-dihydroguaiaretic acid (**15**), and 5,8,4′-trihydroxy-3,7-dimethoxyflavone (**18**), which belong to structural classes of natural products that have shown vasodilatory effects [33].

Considering that stimulation of the NO/cGMP and H_2S/K_{ATP} pathways in endothelial cells importantly contributes to vasorelaxation, we investigated whether the presence of endothelium and activation of these biochemical pathways were involved in the vasorelaxant effect elicited by compounds **3**, **15**, and **18**.

Earlier studies have proved that naturally occurring lupane-, oleanane-, and ursane-type triterpenes elicit vasodilator effects [34–38]. The vasodilation produced by the lupane-type triterpene betulinic acid and the oleanane-type triterpenes moronic, morolic, and 3,4-seco-olean-18-enen-3,28-dioic acids is endothelium-dependent [35]. While, according to different scientific groups, the vasorelaxation evoked by oleanolic acid might be either nearly fully endothelium-dependent or endothelium-dependent and independent [36,38], the cause of this discrepancy has been attributed to the compound employed to pre-contract the vessels, phenylephrine [38] or norepinephrine [36].

In the case of the present study, blockade of the vasodilator activity produced by corosolic acid (**3**) in endothelium-denuded aortas provided evidence that the mechanism underlying this triterpene-induced vasodilation was endothelium-dependent. Supporting this finding, the inhibition of both eNOS and CSE significantly decreased corosolic acid-induced vasodilation, indicating the participation of the NO/cGMP and the H_2S/K_{ATP} pathways in its effect. These signaling pathways activate different potassium channels, subsequently hyperpolarizing the vascular smooth muscle cell membrane, leading to a decrease in the intracellular free calcium level, which finally produces vasodilation [39–44]. In this study, we evaluated whether potassium channel blockers impaired vasodilation provoked by compound **3**. TEA significantly diminished corosolic acid-evoked vasodilation, which confirmed the activation of signaling pathways for NO and H_2S.

Corosolic acid (**3**) is an ursane-type triterpene, which has a similar structure to that of ursolic acid but with an alpha OH group at position 2. Interestingly, our research group previously demonstrated that ursolic acid and uvaol (the alcohol corresponding to ursolic acid) produce an endothelium dependent vasorelaxation, which involves stimulation of the NO/cGMP and H_2S/K_{ATP} pathways. Molecular docking studies showed that both triterpenes are able to bind with high affinity to endothelial NOS and CSE in allosteric binding sites located relatively far from the catalytic sites [34]. We found that corosolic acid (**3**) ($EC_{50} = 108.9 \pm 3.2$ μM; $E_{max} = 96.4 \pm 4.2\%$) is approximately two fold less potent than ursolic acid ($EC_{50} = 47.1 \pm 7.6$ μM; $E_{max} = 97.7 \pm 3.9\%$) and uvaol ($EC_{50} = 43.6 \pm 5.6$ μM; $E_{max} = 93.4 \pm 5.1\%$) [34]. However, these three compounds exhibited a similar maximum vasodilator effect. Considering the great structure resemblance between ursolic acid and corosolic acid (**3**), it is very likely that this latter compound directly activates eNOS and CSE in a similar way to ursolic acid. Both compounds bear a β-OH group at position 3 and an α-carboxyl group at position 28. According to the molecular docking studies of ursolic acid, 3 β-OH forms hydrogen bonds with Asp 480 in eNOS and His 99 in CSE. Whereas, 28 α-carboxyl forms a hydrogen bond with His373 and an electrostatic interaction with Arg367 in eNOS [34]. All these interactions are key in stabilizing protein-ligand binding. It is quite possible that these same types of interactions are established between corosolic acid (**3**) and its enzymatic targets.

In a recent study, Waldbauer et al. carried out a bioassay-guided fractionation of the methanol/water (70:30) extract form apple pomace, employing the ^{14}C-L-arginine to ^{14}C-L-citrulline conversion assay, in a human endothelium cell line, to monitor eNOS activity. Eleven triterpenoid acids, including ursolic and corosolic acids, were isolated from the most active fractions. None of the individual triterpenes increased eNOS activity, but the reconstituted compound mixture did significantly stimulate eNOS [45]. It is important to mention that the range of concentrations of ursolic (1 to 7.5 μM) and corosolic (1 to 15 μM) acids employed to test the activation of eNOS in endothelial cells was lower than in the current study (2.1 μM to 2.1 mM), which may be the reason why Waldbauer et al. did not observe any effect on eNOS.

Several studies have been reported about the biological activities elicited by corosolic acid (**3**), including anti-inflammatory [30], anti-obesity [46], antitumoral [47], and antidiabetic effects [31,32]. However, its action on vascular smooth muscle has not so far been investigated. Yamaguchi et al. (2006) reported that corosolic acid (0.072%), administered in a high fat diet during 14 weeks, lowered blood pressure in male spontaneously hypertensive corpulent rat (SHR-cp) rats, an animal model of metabolic syndrome [48], but the molecular mechanism underlying the hypotensive effect of this triterpene was not clarified. Corosolic acid-induced vasodilator activity may account for the anti-hypertensive properties observed in the SHR-cp rats.

Although NO and H_2S independently elicit a smooth muscle relaxation, there is growing evidence that interaction between the NO/cGMP and H_2S/K_{ATP} pathways leads to an enhancement of the vasorelaxant effect [49], through various mechanisms, which include: stimulation of eNOS activity, stabilization of soluble guanylate cyclase, inhibition of phosphodiesterases, activation of protein kinases [12,49,50], and generation of nitroxyl (HNO), a potent vasodilator [51–53]. Since corosolic acid

(**3**) activates both pathways, it might be considered a valuable lead compound for the development of new drugs useful for the treatment of cardiovascular diseases related to endothelial dysfunction.

Regarding *meso*-dihydroguaiaretic acid (**15**), a variety of biological activities, such as antioxidant [54], anti-inflammatory [55], cytotoxic, and antineoplasic [56,57] effects, have been ascribed to this compound. Concerning the cardiovascular system, it has been documented that this lignan is a moderate platelet-activating factor (PAF) antagonist [58] and an inhibitor of vascular smooth muscle cell proliferation [59]. The present study provides heretofore unknown evidence that compound 15 is capable of inducing vasodilation, via mechanisms that involve endothelium-dependent and independent pathways. The endothelium-dependent component is mainly produced by activation of the NO/cGMP pathway.

Previous studies demonstrated that nordihydroguaiaretic acid, a lignan structurally related to 15, which instead of possessing methoxyl substituents in positions 3 and 3′ has hydroxyl groups, enhances the expression and activity of eNOS in endothelial cells [60] and activates large conductance calcium-dependent potassium (BK) channels in arterial smooth muscle cells [61]. It has been proposed that BK channels opening by nordihydroguaiaretic acid is produced by a direct action on the BK alfa subunit and an increased calcium release from the sarcoplasmic reticulum [62]. In contrast to these findings, our results showed that activation of the potassium channels is not involved in the vasodilator effect elicited by *meso*-dihydroguaiaretic acid (**15**). The reason for this difference might be attributed to the presence of methoxy groups on carbons 3 and 3′ in compound 15. In accordance with this hypothesis, it has been suggested that the presence of the hydroxy group in position 5 in 5-hydroxyflavone is a structural requirement for a possible interaction with BK channels [63].

Considering that stimulation of the potassium channels is not implicated in the vasorelaxant mechanism of *meso*-dihydroguaiaretic acid (**15**), it is possible that activation of the NO/cGMP pathway induced by this lignan produces vasodilation through alternative mechanisms, including the inhibition of calcium influx from voltage-dependent calcium channels and calcium release by the inositol 1,4,5-trisphosphate receptor or increase of the reuptake of cytosolic calcium into the sarcoplasmic reticulum [64]. It is worth highlighting that compound 15 elicited a vasodilator effect with a similar potency to that of ACh, which supports its potential value as a lead compound for the development of new antihypertensive drugs.

On the other hand, the present study represents the first demonstration that 5,8,4′-trihydroxy-3,7-dimethoxyflavone (**18**) is capable of relaxing the arterial smooth muscle. Removal of endothelium significantly decreased, but not completely blocked, the vasorelaxation induced by this flavone, indicating that both endothelial-dependent and independent vasodilation pathways are involved in its mechanism of action. The vasorelaxing effect was significantly diminished in the presence of L-NAME, which evidenced that activation of the NO/cGMP pathway partly contributes to endothelium dependent 5,8,4′-trihydroxy-3,7-dimethoxyflavone-induced vasodilation. Considering the slight rightward shift of the CRCs in the absence of endothelium ($p = 0.009$) and in the presence of L-NAME ($p = 0.99$), it is evident that this compound mainly produces its vasodilator effect through an endothelium-independent mechanism. Our results are in accordance with previous studies which proved that methoxy-flavones, structurally related to compound **18**, elicit vasodilation [65,66], at least partly, through an endothelium-dependent mechanism that involves activation of the NO/cGMP pathway [65]. However, our findings differ from those of other researchers who found that certain methoxy-flavones produce an endothelium-dependent vasodilatory effect via activation of the potassium channels [67,68]. Apparently, differences in the type and position of the substituents on the basic flavone skeleton greatly influence the mechanism underlying the vasodilator effect of these compounds, as evidenced by the fact that 5,4′-dihydroxy-3,7,8,3′-tetramethoxyflavone produces an endothelium-independent vasorelaxation, mediated by potassium channels activation [69], whereas 3,5,7,3′,4′-pentamethoxyflavone induces a vasorelaxant effect, which provokes the release of NO and H_2S, but surprisingly without activating potassium channels [70,71]. In the case of 5,8,4′-trihydroxy-3,7-dimethoxyflavonen (**18**), our results indicate that this compound mainly produces

its vasodilator effect through an endothelium-independent mechanism, which may involve a calcium channel blockade [72,73]. However, this remains to be elucidated.

4. Materials and Methods

4.1. Reagents and Chemicals

Reagents, standards, and solvents used in the pharmacological assays were obtained from Sigma-Aldrich (St. Louis, MO, USA).

4.2. Isolation, Purification and Structural Characterization of Phytochemicals

The phytochemicals evaluated were previously isolated and purified by several chromatographic methods from different plants. The purity of the compounds was determined by one dimension or two-dimension thin layer chromatography and in some cases using high performance liquid chromatography. The chemical structure of compounds was determined by 1D or 2D Nuclear Magnetic Resonance techniques as described previously: *A. adstringens*: 3-α-hydroxymasticadienonic acid (**1**) [74], *C. mexicanum*: 3α-hydroxytirucalla-7,22Z-dien-26-oic acid (**2**) [18], *C. gracilior*: corosolic acid (**3**) [26], *C. alamosanus*: (3*R*,4*R*,6*S*)-*p*-menth-1-eno-3,6-diol (**9**), 5-hydroxy-3,7,4′-trimethoxyflavone (**17**), *C. glabellus*: 6,7-diacetylaustro inulin (**10**), and 6-*O*-acetylaustro inulin (**11**) [75], *G. glauca*: galphin A (**4**), galphin B (**5**), galphimidin (**6**) [24], *J. neopauciflora*: 3β-*trans*-*p*-coumaroyl-oxy-16-β-hydroxy-20(29)-lupene (**7**), β-sitosteryl β-D-glucopyranoside (**8**) [19], *L. tridentata*: 3′-demethoxy-6-*O*-demethyl-isoguaiacin (**14**), *meso*-dihydroguaiaretic acid (**15**), 5,4′-dihydroxy-3,7,8-trimethoxyflavone (**16**), 5,8,4′-trihydroxy-3,7-dimethoxyflavone (**18**) [25], *P. adnata*: perezone (**12**), and pipitzol (**13**) [76], and *T. graveolens*: pinostrobin (**19**) [28].

4.3. Experimental Animals

All experimental procedures were performed in accordance with guidelines of the Mexican Official Standard NOM-062-ZOO-1999 [74], and approved by the Bioethics Committee of the Deparment of Postgraduate, Research and Innovation of the Autonomous University of Querétaro, México (Approval number 290/SPII/2018). Wistar male rats (250–300 g) were provided by the Institute of Neurobiology of the National Autonomous University of Mexico, Campus Juriquilla. Animals were housed in standard cages under controlled temperature conditions with a 12:12 h light-dark cycle. Water and food were provided ad libitum.

4.4. Determination of the Vasodilator Effect of the Selected Secondary Metabolites

4.4.1. Isolated Rat Aorta Assay

Rats were sacrificed by decapitation. The thoracic aorta was surgically removed and placed in a Petri dish containing ice-cold (4 °C) Krebs-Henseleit solution with the following composition (mM): 126.8 NaCl; 5.9 KCl; 1.2 KH_2PO_4; 1.2 $MgSO_4$; 5.0 D-glucose; 30 $NaHCO_3$; 2.5 $CaCl_2$ (pH 7.4), bubbled with a mixture of carbogen (95% O_2 and 5% CO_2). Then, the intraluminal space of the aorta was rinsed with fresh solution to prevent clot formation, cleaned from surrounding connective tissue, and sliced into rings (3–4 mm in length). Aortic rings were mounted between two metallic hooks, with one being fixed and the other attached to an isometric transducer, and placed into organ baths chambers containing pre-warmed Krebs-Henseleit solution (37 °C) gassed with carbogen. The aortic segments were allowed to equilibrate for 60 min under a resting tension of 1.5 g. During the resting period, the organ bath solution was replaced every 10 min. In order to stimulate the vascular smooth muscle, the tissues were contracted with KCl solution (100 mM). Once a stable contractile tone had been reached, the bathing medium was replaced every 10 min to restore the initial resting tension. Afterwards, the aortic rings were contracted with 1 μM L-phenylephrine (Phe); the contractile force induced was defined as 100%, and once the plateau was reached, the test compounds were cumulatively

added. Acetylcholine was dissolved in distilled water, while the selected compounds were dissolved in dimethyl sulfoxide (DMSO) and diluted in distilled water. The highest concentration of DMSO was 0.2% (*v/v*). When used, pharmacological inhibitors were added to the organ bath chambers 20 min before the addition of Phe. Changes in tension caused by the tested concentrations were detected by Grass FT03 force transducers coupled to a Grass 7D Polygraph (Grass Instrument Co, Quincy, MA, USA); they were expressed as percentages of relaxation based on the contraction generated by adding Phe [77].

4.4.2. Participation of the Endothelium in the Vasorelaxant Response of Compounds **3**, **15**, and **18**

To determine whether the vasorelaxant response of compounds **3**, **15**, and **18** was dependent on the vascular endothelium, assays on aorta segments without endothelium were performed. In these experiments, the endothelium was removed by flushing the lumen of the aorta with 0.2% desoxycholic acid in saline solution 0.9%, as previously reported [77]. The absence of endothelium was confirmed at the start of the experiments, showing that the addition of 1 μM of ACh did not induce more than 5% relaxation.

4.5. Evaluation of the Participation of the NO/cGMP and H_2S/K_{ATP} Channel Pathways in the Vasodilator Response of Compounds **3**, **15**, *and* **18**

Involvement of the NO/cGMP and the H_2S/K_{ATP} channel pathways in the vasodilator effect of compounds **3**, **15**, and **18** was evaluated by incubating intact endothelium aortic rings for 20 min in the presence of inhibitors of specific enzymes of each of these pathways: (1) NO/cGMP pathway: 100 μM N^G-nitro-l-arginine methyl ester (L-NAME, inhibitor of eNOS); and (2) H_2S/K_{ATP} channel pathway: 10 mM dl-propargylglycine (PAG, inhibitor of CSE) [34,78,79].

To assess whether activation of the K^+ channels was involved in the vasodilation produced by compounds **3**, **15**, and **18**, the effect of pretreatment with the non-selective potassium channel blocker, 1 mM TEA, was evaluated [80,81].

4.6. Statistical Analysis

Evaluations of each concentration of the tested substances were performed on aortas obtained from at least three different rats (*n* = 3) with two replicas.

All values are expressed as the mean ± standard error of the mean (SEM). The resulting data obtained from each evaluation were fitted to a sigmoidal equation, plotted, and analyzed to calculate EC_{50} and Emax (GraphPad Prism 7.02, San Diego, CA, USA).

In the case of endothelium-dependent evaluations, analysis by an unpaired *t*-test was conducted to test differences between the EC_{50}s of each compound in the presence and absence of endothelium. While CRC in the presence of inhibitors was analyzed by one-way analysis of variance (ANOVA) followed by the Turkey test to evaluate any significant differences between the means. Values of $p < 0.01$ were considered to be significant.

5. Conclusions

This study demonstrates that 19 natural products obtained from plants widely employed in Mexican traditional medicine are able to modify the tone of arterial smooth muscle. The most potent vasodilatory compounds were corosolic acid (**3**), *meso*-dihydroguaiaretic acid (**15**), and 5,8,4′-trihydroxy-3,7-dimethoxyflavone (**18**). These secondary metabolites represent valuable leads for the development of drugs useful in the treatment of cardiovascular diseases. Corosolic acid induces vasodilation by a mechanism that involves activation of the NO/cGMP and H_2S/K_{ATP} pathways. Additionally, the vasodilator effect of *meso*-dihydroguaiaretic acid and 5,8,4′-trihydroxy-3,7-dimethoxyflavone partly involves stimulation of the NO/cGMP pathway. However, these compounds also showed an important endothelium-independent vasorelaxant effect, whose mechanism of action remains to be clarified. Our findings confirm that plants traditionally

used with medicinal purposes constitute an important reservoir of bioactive compounds that deserves intensive scientific exploration.

References

1. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* **2002**, *360*, 1903–1913.

2. Rapsomaniki, E.; Timmis, A.; George, J.; Pujades-Rodriguez, M.; Shah, A.D.; Denaxas, S.; White, I.R.; Caulfield, M.J.; Deanfield, J.E.; Smeeth, L. Blood pressure and incidence of twelve cardiovascular diseases: Lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. *Lancet* **2014**, *383*, 1899–1911. [CrossRef]

3. Wu, F.; Guo, Y.; Chatterji, S.; Zheng, Y.; Naidoo, N.; Jiang, Y.; Biritwum, R.; Yawson, A.; Minicuci, N.; Salinas-Rodriguez, A. Common risk factors for chronic non-communicable diseases among older adults in China, Ghana, Mexico, India, Russia and South Africa: The study on global AGEing and adult health (SAGE) wave 1. *BMC Public Health* **2015**, *15*, 88. [CrossRef] [PubMed]

4. World Health Organization. The Top Ten Causes of Death. Available online: http://www.who.int/mediacentre/factsheets/fs310/en/ (accessed on 17 February 2017).

5. Bakris, G.; Sarafidis, P.; Agarwal, R.; Ruilope, L. Review of blood pressure control rates and outcomes. *J. Am. Soc. Hypertens.* **2014**, *8*, 127–141. [CrossRef] [PubMed]

6. Mills, K.T.; Bundy, J.D.; Kelly, T.N.; Reed, J.E.; Kearney, P.M.; Reynolds, K.; Chen, J.; He, J. Global disparities of hypertension prevalence and control. *Circulation* **2016**, *134*, 441–450. [CrossRef] [PubMed]

7. Düsing, R.; Waeber, B.; Destro, M.; Maia, C.S.; Brunel, P. Triple-combination therapy in the treatment of hypertension: A review of the evidence. *J. Hum. Hypertens.* **2017**, *31*, 501. [CrossRef] [PubMed]

8. Laurent, S. Antihypertensive drugs. *Pharmacol. Res.* **2017**, *124*, 116–125. [CrossRef] [PubMed]

9. Triggle, C.R.; Samuel, S.M.; Ravishankar, S.; Marei, I.; Arunachalam, G.; Ding, H. The endothelium: Influencing vascular smooth muscle in many ways. *Can. J. Physiol. Pharmacol.* **2012**, *90*, 713–738. [CrossRef] [PubMed]

10. Kang, K.-T. Endothelium-derived relaxing factors of small resistance arteries in hypertension. *Toxicol. Res.* **2014**, *30*, 141–148. [CrossRef] [PubMed]

11. Tousoulis, D.; Simopoulou, C.; Papageorgiou, N.; Oikonomou, E.; Hatzis, G.; Siasos, G.; Tsiamis, E.; Stefanadis, C. Endothelial dysfunction in conduit arteries and in microcirculation. Novel therapeutic approaches. *Pharmacol. Ther.* **2014**, *144*, 253–267. [CrossRef] [PubMed]

12. Yuan, S.; Patel, R.P.; Kevil, C.G. Working with nitric oxide and hydrogen sulfide in biological systems. *Am. J. Physiol.-Lung Cell. Mol. Physiol.* **2015**, *308*, L403–L415. [CrossRef] [PubMed]

13. Daiber, A.; Steven, S.; Weber, A.; Shuvaev, V.V.; Muzykantov, V.R.; Laher, I.; Li, H.; Lamas, S.; Münzel, T. Targeting vascular (endothelial) dysfunction. *Br. J. Pharmacol.* **2017**, *174*, 1591–1619. [CrossRef] [PubMed]

14. Vanhoutte, P.; Shimokawa, H.; Feletou, M.; Tang, E. Endothelial dysfunction and vascular disease—A 30th anniversary update. *Acta Physiol.* **2017**, *219*, 22–96. [CrossRef] [PubMed]

15. Hernández, F. *Historia Natural de Nueva España*; Universidad Nacional de México: Mexico D.F., Mexico, 1959. (In Spanish)

16. De la Cruz, M. *Libellus de medicinalibus indorum herbis: Aztec manuscript of 1552 (as latin traduction of Juan Badiano)*; Fondo de Cultura Economica; Instituto Mexicano del Seguro Social: Mexico D.F., Mexico, 1991. (In Spanish)

17. Díaz, J. *Uso de las Plantas Medicinales de México*; Instituto Mexicano para el Estudio de las Plantas Medicinales: Mexico D.F., Mexico, 1976; p. 329. (In Spanish)

18. Camacho, M.d.R.; Mata, R.; Castaneda, P.; Kirby, G.C.; Warhurst, D.C.; Croft, S.L.; Phillipson, J.D. Bioactive compounds from *Celaenodendron mexicanum*. *Planta Med.* **2000**, *66*, 463–468. [CrossRef] [PubMed]

19. García, A.; Delgado, G. Uncommon sesquiterpenoids and new triterpenoids from *Jatropha neopauciflora* (Euphorbiaceae). *Helvetica Chimica Acta* **2006**, *89*, 16–29. [CrossRef]

20. Biblioteca Digital de la Medicina Tradicional Mexicana. Available online: http://www.medicinatradicionalmexicana.unam.mx/index.php (accessed on 30 January 2018).

21. Hernández-Hernández, A.; Alarcón-Aguilar, F.; Jiménez-Estrada, M.; Hernández-Portilla, L.; Flores-Ortiz, C.; Rodríguez-Monroy, M.; Canales-Martínez, M. Biological properties and chemical composition of *Jatropha neopauciflora* pax. *Afr. J. Tradit. Complement. Altern. Med.* **2017**, *14*, 32. [CrossRef] [PubMed]

22. Arrieta, J.; Siles-Barrios, D.; García-Sánchez, J.; Reyes-Trejo, B.; Sánchez-Mendoza, M.E. Relaxant effect of the extracts of *Crataegus mexicana* on guinea pig tracheal smooth muscle. *Pharmacogn. J.* **2010**, *2*, 40–46. [CrossRef]

23. Estrada-Muñiz, E.; Guerrero-Palomo, G.; Vega, L. Natural products: New anti-cancer agents derived from plants. *Curr. Top. Toxicol.* **2012**, *8*, 19–32.

24. Camacho, M.D.R.; Phillipson, J.D.; Croft, S.L.; Marley, D.; Kirby, G.C.; Warhurst, D.C. Assessment of the antiprotozoal activity of *Galphimia glauca* and the isolation of new nor-secofriedelanes and nor-friedelanes. *J. Nat. Prod.* **2002**, *65*, 1457–1461. [CrossRef]

25. Favela-Hernández, J.; García, A.; Garza-González, E.; Rivas-Galindo, V.; Camacho-Corona, M.d.R. Antibacterial and antimycobacterial lignans and flavonoids from *Larrea tridentata*. *Phytother. Res.* **2012**, *26*, 1957–1960. [CrossRef] [PubMed]

26. Hernández-Pérez, A.; Bah, M.; Ibarra-Alvarado, C.; Rivero-Cruz, J.F.; Rojas-Molina, A.; Rojas-Molina, J.I.; Cabrera-Luna, J.A. Aortic relaxant activity of *Crataegus gracilior* Phipps and identification of some of its chemical constituents. *Molecules* **2014**, *19*, 20962–20974. [CrossRef] [PubMed]

27. Canales, M.; Hernández, T.; Caballero, J.; De Vivar, A.R.; Avila, G.; Duran, A.; Lira, R. Informant consensus factor and antibacterial activity of the medicinal plants used by the people of San Rafael Coxcatlán, Puebla, México. *J. Ethnopharmacol.* **2005**, *97*, 429–439. [CrossRef] [PubMed]

28. Camacho, M.D.R.; Sanchez, B.; Quiroz, H.; Contreras, J.L.; Mata, R. Pinocembrine: A bioactive flavanone from *Teloxys graveolens*. *J. Ethnopharmacol.* **1991**, *31*, 383–389. [CrossRef]

29. Calzada, F.; Velázquez, C.; Cedillo-Rivera, R.; Esquivel, B. Antiprotozoal activity of the constituents of *Teloxys graveolens*. *Phytother. Res.* **2003**, *17*, 731–732. [CrossRef] [PubMed]

30. Kim, S.-J.; Cha, J.-Y.; Kang, H.S.; Lee, J.-H.; Lee, J.Y.; Park, J.-H.; Bae, J.-H.; Song, D.-K.; Im, S.-S. Corosolic acid ameliorates acute inflammation through inhibition of IRAK-1 phosphorylation in macrophages. *BMB Rep.* **2016**, *49*, 276. [CrossRef] [PubMed]

31. Nazaruk, J.; Borzym-Kluczyk, M. The role of triterpenes in the management of diabetes mellitus and its complications. *Phytochem. Rev.* **2015**, *14*, 675–690. [CrossRef] [PubMed]

32. Li, X.-Q.; Tian, W.; Liu, X.-X.; Zhang, K.; Huo, J.-C.; Liu, W.-J.; Li, P.; Xiao, X.; Zhao, M.-G.; Cao, W. Corosolic acid inhibits the proliferation of glomerular mesangial cells and protects against diabetic renal damage. *Sci. Rep.* **2016**, *6*, 26854. [CrossRef] [PubMed]

33. Luna-Vázquez, F.J.; Ibarra-Alvarado, C.; Rojas-Molina, A.; Rojas-Molina, I.; Zavala-Sánchez, M.Á. Vasodilator compounds derived from plants and their mechanisms of action. *Molecules* **2013**, *18*, 5814–5857. [CrossRef] [PubMed]

34. Luna-Vázquez, F.J.; Ibarra-Alvarado, C.; Rojas-Molina, A.; Romo-Mancillas, A.; López-Vallejo, F.H.; Solís-Gutiérrez, M.; Rojas-Molina, J.I.; Rivero-Cruz, F. Role of nitric oxide and hydrogen sulfide in the vasodilator effect of ursolic acid and uvaol from black cherry *Prunus serotina* fruits. *Molecules* **2016**, *21*, 78. [CrossRef] [PubMed]

35. Rios, M.Y.; López-Martínez, S.; López-Vallejo, F.; Medina-Franco, J.L.; Villalobos-Molina, R.; Ibarra-Barajas, M.; Navarrete-Vazquez, G.; Hidalgo-Figueroa, S.; Hernández-Abreu, O.; Estrada-Soto, S. Vasorelaxant activity of some structurally related triterpenic acids from *Phoradendron reichenbachianum* (Viscaceae) mainly by NO production: Ex vivo and in silico studies. *Fitoterapia* **2012**, *83*, 1023–1029. [CrossRef] [PubMed]

36. Rodriguez-Rodriguez, R. Oleanolic acid and related triterpenoids from olives on vascular function: Molecular mechanisms and therapeutic perspectives. *Curr. Med. Chem.* **2015**, *22*, 1414–1425. [CrossRef] [PubMed]

37. Jin, S.W.; Choi, C.Y.; Hwang, Y.P.; Kim, H.G.; Kim, S.J.; Chung, Y.C.; Lee, K.J.; Jeong, T.C.; Jeong, H.G. Betulinic acid increases eNOS phosphorylation and no synthesis via the calcium-signaling pathway. *J. Agric. Food Chem.* **2016**, *64*, 785–791. [CrossRef] [PubMed]

38. Madlala, H.P.; Metzinger, T.; van Heerden, F.R.; Musabayane, C.T.; Mubagwa, K.; Dessy, C. Vascular endothelium-dependent and independent actions of oleanolic acid and its synthetic oleanane derivatives as possible mechanisms for hypotensive effects. *PLoS ONE* **2016**, *11*, e0147395. [CrossRef] [PubMed]

39. White, R.E.; Kryman, J.P.; El-Mowafy, A.M.; Han, G.; Carrier, G.O. Camp-dependent vasodilators cross-activate the cGMP-dependent protein kinase to stimulate BKCa channel activity in coronary artery smooth muscle cells. *Circ. Res.* **2000**, *86*, 897–905. [CrossRef] [PubMed]

40. Boerth, N.J.; Dey, N.B.; Cornwell, T.L.; Lincoln, T.M. Cyclic GMP-dependent protein kinase regulates vascular smooth muscle cell phenotype. *J. Vasc. Res.* **1997**, *34*, 245–259. [CrossRef] [PubMed]

41. Zhang, Z.; Huang, H.; Liu, P.; Tang, C.; Wang, J. Hydrogen sulfide contributes to cardioprotection during ischemia–reperfusion injury by opening K_{ATP} channels. *Can. J. Physiol. Pharmacol.* **2007**, *85*, 1248–1253. [CrossRef] [PubMed]

42. Zhao, W.; Zhang, J.; Lu, Y.; Wang, R. The vasorelaxant effect of H_2S as a novel endogenous gaseous K_{ATP} channel opener. *EMBO J.* **2001**, *20*, 6008–6016. [CrossRef] [PubMed]

43. Yoo, D.; Jupiter, R.C.; Pankey, E.A.; Reddy, V.G.; Edward, J.A.; Swan, K.W.; Peak, T.C.; Mostany, R.; Kadowitz, P.J. Analysis of cardiovascular responses to the H_2S donors na Na_2S and NaHS in the rat. *Am. J. Physiol.-Heart Circ. Physiol.* **2015**, *309*, H605–H614. [CrossRef] [PubMed]

44. Mustafa, A.K.; Gadalla, M.M.; Snyder, S.H. Signaling by gasotransmitters. *Sci. Signal.* **2009**, *2*, re2. [CrossRef] [PubMed]

45. Waldbauer, K.; Seiringer, G.n.; Nguyen, D.L.; Winkler, J.; Blaschke, M.; McKinnon, R.; Urban, E.; Ladurner, A.; Dirsch, V.M.; Zehl, M. Triterpenoic acids from apple pomace enhance the activity of the endothelial nitric oxide synthase (eNOS). *J. Agric. Food Chem.* **2015**, *64*, 185–194. [CrossRef] [PubMed]

46. Yamada, K.; Hosokawa, M.; Yamada, C.; Watanabe, R.; Fujimoto, S.; Fujiwara, H.; Kunitomo, M.; Miura, T.; Kaneko, T.; Tsuda, K. Dietary corosolic acid ameliorates obesity and hepatic steatosis in KK-Ay mice. *Biol. Pharm. Bull.* **2008**, *31*, 651–655. [CrossRef] [PubMed]

47. Kim, J.-H.; Kim, Y.H.; Song, G.-Y.; Kim, D.-E.; Jeong, Y.-J.; Liu, K.-H.; Chung, Y.-H.; Oh, S. Ursolic acid and its natural derivative corosolic acid suppress the proliferation of APC-mutated colon cancer cells through promotion of β-catenin degradation. *Food Chem. Toxicol.* **2014**, *67*, 87–95. [CrossRef] [PubMed]

48. Yamaguchi, Y.; Yamada, K.; Yoshikawa, N.; Nakamura, K.; Haginaka, J.; Kunitomo, M. Corosolic acid prevents oxidative stress, inflammation and hypertension in SHR/NDmcr-cp rats, a model of metabolic syndrome. *Life Sci.* **2006**, *79*, 2474–2479. [CrossRef] [PubMed]

49. Szabo, C. Hydrogen sulfide, an enhancer of vascular nitric oxide signaling: Mechanisms and implications. *Am. J. Physiol.-Cell Physiol.* **2017**, *312*, C3–C15. [CrossRef] [PubMed]

50. Zhou, Z.; Martin, E.; Sharina, I.; Esposito, I.; Szabo, C.; Bucci, M.; Cirino, G.; Papapetropoulos, A. Regulation of soluble guanylyl cyclase redox state by hydrogen sulfide. *Pharmacol. Res.* **2016**, *111*, 556–562. [CrossRef] [PubMed]

51. Bełtowski, J.; Jamroz-Wiśniewska, A. Hydrogen sulfide and endothelium-dependent vasorelaxation. *Molecules* **2014**, *19*, 21183–21199. [CrossRef] [PubMed]

52. Andrews, K.L.; Lumsden, N.G.; Farry, J.; Jefferis, A.-M.; Kemp-Harper, B.K.; Chin-Dusting, J.P. Nitroxyl: A vasodilator of human vessels that is not susceptible to tolerance. *Clin. Sci.* **2015**, *129*, 179–187. [CrossRef] [PubMed]

53. Nagpure, B.; Bian, J.-S. Interaction of hydrogen sulfide with nitric oxide in the cardiovascular system. *Oxid. Med. Cell. Longev.* **2016**, 6904327. [CrossRef] [PubMed]

54. Ma, C.J.; Kim, S.R.; Kim, J.; Kim, Y.C. *Meso*-dihydroguaiaretic acid and licarin a of *Machilus thunbergii* protect against glutamate-induced toxicity in primary cultures of a rat cortical cells. *Br. J. Pharmacol.* **2005**, *146*, 752–759. [CrossRef] [PubMed]

55. Moon, T.C.; Seo, C.S.; Haa, K.; Kim, J.C.; Hwang, N.K.; Hong, T.G.; Kim, J.H.; Kim, D.H.; Son, J.K.; Chang, H.W. *Meso*-dihydroguaiaretic acid isolated from *Saururus chinensis* inhibits cyclooxygenase-2 and 5-lipoxygenase in mouse bone marrow-derived mast cells. *Arch. Pharm. Res.* **2008**, *31*, 606–610. [CrossRef] [PubMed]

56. Min, B.S.; Trang, T.T.T. Compounds from the aerial part of *Saururus chinensis* and their cytotoxic activity. *Nat. Prod. Sci.* **2012**, *18*, 227–232.

57. Choi, M.S.; Jeong, H.J.; Kang, T.-h.; Shin, H.-M.; Oh, S.T.; Choi, Y.; Jeon, S. Meso-dihydroguaiaretic acid induces apoptosis and inhibits cell migration via p38 activation and EGFR/Src/intergrin β3 downregulation in breast cancer cells. *Life Sci.* **2015**, *141*, 81–89. [CrossRef] [PubMed]

58. Ghisalberti, E. Cardiovascular activity of naturally occurring lignans. *Phytomedicine* **1997**, *4*, 151–166. [CrossRef]

59. Song, M.-C.; Kim, E.-C.; Kim, W.-J.; Kim, T.-J. Meso-dihydroguaiaretic acid inhibits rat aortic vascular smooth muscle cell proliferation by suppressing phosphorylation of platelet-derived growth factor receptor beta. *Eur. J. Pharmacol.* **2014**, *744*, 36–41. [CrossRef] [PubMed]

60. Ramasamy, S.; Drummond, G.R.; Ahn, J.; Storek, M.; Pohl, J.; Parthasarathy, S.; Harrison, D.G. Modulation of expression of endothelial nitric oxide synthase by nordihydroguaiaretic acid, a phenolic antioxidant in cultured endothelial cells. *Mol. Pharmacol.* **1999**, *56*, 116–123. [CrossRef] [PubMed]

61. Yamamura, H.; Nagano, N.; Hirano, M.; Muraki, K.; Watanabe, M.; Imaizumi, Y. Activation of Ca^{2+}-dependent K^+ current by nordihydroguaiaretic acid in porcine coronary arterial smooth muscle cells. *J. Pharmacol. Exp. Ther.* **1999**, *291*, 140–146. [PubMed]

62. Yamamura, H.; Sakamoto, K.; Ohya, S.; Muraki, K.; Imaizumi, Y. Mechanisms underlying the activation of large conductance Ca^{2+}-activated K^+ channels by nordihydroguaiaretic acid. *Jap. J. Pharmacol.* **2002**, *89*, 53–63. [CrossRef] [PubMed]

63. Calderone, V.; Chericoni, S.; Martinelli, C.; Testai, L.; Nardi, A.; Morelli, I.; Breschi, M.C.; Martinotti, E. Vasorelaxing effects of flavonoids: Investigation on the possible involvement of potassium channels. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **2004**, *370*, 290–298. [CrossRef] [PubMed]

64. Zhao, Y.; Vanhoutte, P.M.; Leung, S.W. Vascular nitric oxide: Beyond eNOS. *J. Pharmacol. Sci.* **2015**, *129*, 83–94. [CrossRef] [PubMed]

65. Morán-Pinzón, J.; Mondolis, E.; Abad, A.; Amaro-Luis, J.M.; Sevilla, M.Á.; Montero, M.J.; López-Pérez, J.L.; Guerrero De León, E. Vasorelaxan effect and potent antioxidant activity of natural flavones isolated from *Lourteigia stoechadifolia* and *Ageratina stevioides*, two venezuelan plants. *Eur. J. Med. Plants* **2017**, *18*, 1–10. [CrossRef]

66. Bertin, R.; Chen, Z.; Martinez-Vazquez, M.; Garcia-Argaez, A.; Froldi, G. Vasodilation and radical-scavenging activity of imperatorin and selected coumarinic and flavonoid compounds from genus *Casimiroa*. *Phytomedicine* **2014**, *21*, 586–594. [CrossRef] [PubMed]

67. Tep-areenan, P.; Sawasdee, P.; Randall, M. Possible mechanisms of vasorelaxation for 5, 7-dimethoxyflavone from *Kaempferia parviflora* in the rat aorta. *Phytother. Res.* **2010**, *24*, 1520–1525. [CrossRef] [PubMed]

68. Yam, M.F.; Tan, C.S.; Ahmad, M.; Shibao, R. Mechanism of vasorelaxation induced by eupatorin in the rats aortic ring. *Eur. J. Pharmacol.* **2016**, *789*, 27–36. [CrossRef] [PubMed]

69. Suárez, P.A.; Navarro-Huerta, M.P.; Valle-Aguilera, J.R.; Brito-Orta, M.D.; Rodriguez-Menchaca, A.; Arechiga-Figueroa, I.; Espinosa-Tanguma, R.; Gonzalez-Chavez, M. On the mechanism of action of the relaxing effect of the 5, 4′-dihidroxi-6, 7, 8, 3′-tetrametoxi-flavone, flavone A, on vascular smooth muscle of the rat. *FASEB J.* **2015**, *29*, 773–778.

70. Yorsin, S.; Sukpondma, Y.; Jansakul, C. Vasorelaxant effects of 3, 5, 7, 3′, 4′-pentamethoxyflavone isolated from *Kaempferia parviflora*: Partly stimulating the release of NO and H_2S by rat thoracic aorta. *J. Physiol. Biomed. Sci.* **2015**, *28*, 5–14.

71. Yorsin, S.; Kanokwiroon, K.; Radenahmad, N.; Jansakul, C. Increased vascular eNOS and cystathionine-γ-lyase protein after 6 weeks oral administration of 3, 5, 7, 3′, 4′-pentamethoxyflavone to middle-aged male rats. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **2016**, *389*, 1183–1194. [CrossRef] [PubMed]

72. Fusi, F.; Spiga, O.; Trezza, A.; Sgaragli, G.; Saponara, S. The surge of flavonoids as novel, fine regulators of cardiovascular Ca$_V$ channels. *Eur. J. Pharmacol.* **2017**, *796*, 158–174. [CrossRef] [PubMed]

73. Wani, S.A.; Iqbal, H.; Basir, S.F. Mechanism of flavonoids action in smooth muscle relaxation. *WJPPS* **2017**, *6*, 514–550.

74. Arrieta, J.; Benitez, J.; Flores, E.; Castillo, C.; Navarrete, A. Purification of gastroprotective triterpenoids from the stem bark of *Amphipterygium adstringens*; role of prostaglandins, sulfhydryls, nitric oxide and capsaicin-sensitive neurons. *Planta Med.* **2003**, *69*, 905–909. [PubMed]

75. García, A.; Ramírez-Apan, T.; Cogordan, J.A.; Delgado, G. Absolute configuration assignments by experimental and theoretical approaches of *ent*-labdane-and *cis-ent*-clerodane-type diterpenes isolated from *Croton glabellus*. *Can. J. Chem.* **2006**, *84*, 1593–1602. [CrossRef]

76. Burgueño-Tapia, E.; Castillo, L.; González-Coloma, A.; Joseph-Nathan, P. Antifeedant and phytotoxic activity of the sesquiterpene *p*-benzoquinone perezone and some of its derivatives. *J. Chem. Ecol.* **2008**, *34*, 766. [CrossRef] [PubMed]

77. Ibarra-Alvarado, C.; Rojas, A.; Mendoza, S.; Bah, M.; Gutiérrez, D.; Hernández-Sandoval, L.; Martínez, M. Vasoactive and antioxidant activities of plants used in Mexican traditional medicine for the treatment of cardiovascular diseases. *Pharm. Biol.* **2010**, *48*, 732–739. [CrossRef] [PubMed]

78. Galle, J.; Zabel, U.; Hübner, U.; Hatzelmann, A.; Wagner, B.; Wanner, C.; Schmidt, H.H. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. *Br. J. Pharmacol.* **1999**, *127*, 195–203. [CrossRef] [PubMed]

79. Gonzalez, C.; Rosas-Hernandez, H.; Jurado-Manzano, B.; Ramirez-Lee, M.A.; Salazar-Garcia, S.; Martinez-Cuevas, P.P.; Velarde-Salcedo, A.J.; Morales-Loredo, H.; Espinosa-Tanguma, R.; Ali, S.F. The prolactin family hormones regulate vascular tone through NO and prostacyclin production in isolated rat aortic rings. *Acta Pharmacol. Sinica* **2015**, *36*, 572–586. [CrossRef] [PubMed]

80. Shen, M.; Zhao, L.; Wu, R.-X.; Yue, S.-Q.; Pei, J.-M. The vasorelaxing effect of resveratrol on abdominal aorta from rats and its underlying mechanisms. *Vasc. Pharmacol.* **2013**, *58*, 64–70. [CrossRef] [PubMed]

81. Stott, J.B.; Jepps, T.A.; Greenwood, I.A. Kv7 potassium channels: A new therapeutic target in smooth muscle disorders. *Drug Disc. Today* **2014**, *19*, 413–424. [CrossRef] [PubMed]

Sample Availability: Samples of the compounds 3-α-hydroxymasticadienonic acid, 3α-hydroxytirucalla-7,22Z-dien-26-oic acid, corosolic acid, galphin A, galphin B, galphimidin, 3β-*trans-p*-coumaroyl-oxy-16-β-hydroxy-20(29)-lupene; β-sitosteryl β-D-glucopyranoside; (3*R*,4*R*,6*S*)- *p*-menth-1-eno-3,6-diol, 6,7-diacetylaustro inulin; 6-*O*-acetylaustro inulin; perezon; pipitzol; 3′-demethoxy-6-*O*-demethyl-isoguaiacin; *meso*-dihydroguaiaretic acid; 5,4′-dihydroxy-3,7,8-trimethoxyflavone; 5-hydroxy-3,7,4′-trimethoxyflavone; 5,8,4´-trihydroxy-3,7-dimethoxyflavone; and pinostrobin are available from the authors.